Alere and FIND lengthen partnership for malaria and sleeping sickness tests
The two organizations hope their extended collaboration will further their research and development of a novel rapid diagnostic test (RDT) that will detect both malaria and human African trypanosomiasis (HAT), which is also known as sleeping sickness. The two illnesses are prevalent in 36 impoverished, sub-Saharan African countries, creating another socioeconomic hurdle the communities must face.
“FIND’s role in supporting SD/Alere’s development of a dual test will include collection of clinical samples and leading clinical trials,” FIND CEO Catharina Boehme said. “We are pleased to support the development and evaluation of this combo test."
Boehme said if it proves effective, the test will facilitate detection of residual HAT infections at an early stage, eliminating their ability to serve as disease reservoirs and enhancing hopes to eliminate the disease.
“This important work will be an extension of the successful partnership that has been established with FIND to support the development and evaluation of tests for HAT, leishmaniasis, Buruli ulcer, tuberculosis and malaria, and reaffirms SD/Alere’s commitment to the fight against neglected tropical diseases,” Standard Diagnostics/Alere's Vice President Byung-Ki Cho said. “We are convinced that development of the malaria/HAT combo test will be another key milestone towards elimination of HAT.”